Sysmex : Announcement of Organizational and Personnel Changes(PDF：457KB)

March 6, 2017 Sysmex Corporation

Announcement of Organizational and Personnel Changes

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces today its decision to implement organizational and personnel changes, effective April 1, 2017, as detailed below.

These organizational changes include progressively eliminating the business unit structure, as well as reinforcing the business development structure and accelerating strategy deployment in order to achieve further growth.

1. Organizational Changes

2. Reinforce the business development structure to achieve further growth

3. Reinforce a highly efficient business development structure in core businesses (the hematology, urinalysis, hemostasis, immunochemistry and clinical chemistry fields)

   • We will newly establish the HU Business Development Division to globally oversee processes from strategic planning to the market launch of products in the hematology and urinalysis fields.

     (HU: The initial letters of hematology and urinalysis)

   • We will newly establish the ICH Business Development Division to globally oversee processes from strategic planning to the market launch of products in the hemostasis, immunochemistry and clinical chemistry fields.

     (ICH: The initial letters of immunochemistry, clinical chemistry and hemostasis)

   • We will newly establish the Engineering 1 Division to handle reagent development in our core businesses.

   • We will newly establish the Engineering 2 Division to handle instrument and system development in our core businesses.

   • These four divisions will arrange appropriate strategy-based projects to foster highly efficient organizational operations featuring coordination and cooperation and to increase business execution speed.

4. Reinforce the business development structure for our next core businesses (gene testing and other new business domains utilizing proprietary Sysmex technologies)

   • We will newly establish the LS Business Division to globally oversee processes from strategic planning to the market launch of products, and product development in gene testing and lab assay services.

     (LS: life science)

   • We will newly establish the Clinical Innovation Division to establish new clinical value by fostering the rapid market introduction of newly created technologies for research.

   • We will newly establish the MR Business Development Division to promote marketing, sales and services for medical robots.

     (MR: medical robot)

5. Reinforce the business development structure to create value across fields

   • In addition to performing Group-wide strategic business planning, we will consolidate in the Business Strategy Development Division the global oversight of processes from strategic planning to the market launch of products in the FCM, network solutions, laboratory automation, and research and industry

     markets.

     • We will establish the Clinical Affairs Department, which plans and designs clinical evaluation tests, within the Scientific Affairs Division in the aim of accelerating regulatory approvals in various countries.

6. Reinforce the structure to accelerate strategy deployment

7. Strengthen the human resources and general affairs functions

   • In line with the expansion of our global business scale, we will newly establish the Human Resources Division to secure human resources who can be active globally, reinforce training and promote diversity.

   • In line with an increase in the number of affiliated companies in tandem with our growing scale of business, we will newly establish the General Affairs Division to reinforce global risk management and compliance.

8. Strengthen the R&D support function

   • We will newly establish the Technology Strategy Division to promote technology strategy planning for the Group.

   • We will newly establish the Intellectual Property Division to enhance the Group's intellectual property functions.

9. Strengthen bio-diagnostic reagent technology development

   • We will newly establish the Bio-Diagnostic Reagent Technology Center to handle the development of materials for bio-diagnostic reagents.

10. Strengthen the manufacturing and quality assurance functions

    • We will newly establish the Reagent Manufacturing Management Department and the Manufacturing Information Management Department within the Manufacturing Management Division to prepare strategies related to global reagent production, and heighten cooperation within the Group, thereby accelerating high-quality production.

    • We will newly establish the Quality Control Department within the Instrument Production Division to strengthen the quality control function related to instrument manufacturing.

    • We will establish the PSI Department within the SCM Division to prepare highly precise production plans based on global instrument and reagent demand forecasts.

      (PSI: production, sales and inventory)

11. Reconfigure the global sales and service functions

    • We will newly establish the JEA Region Division to integrate the sales and service functions for the Japan and East Asia (South Korea, Taiwan and Mongolia) region.

    • We will newly establish the Global Support Division to integrate the global service and support function and the overseas sales and service support function.

      New Organizational Structure

      Previous Organizational Structure

12. Personnel Changes and Appointments

13. Appointments of Senior Executive Officers (Promotions)

    Name	New Position	Current Position
    Kaoru Asano	Member of the Managing Board and Senior Executive Officer Senior Managing Director	Member of the Managing Board and Senior Executive Officer Managing Director
    Kenji Tachibana	Member of the Managing Board and Senior Executive Officer Senior Managing Director	Member of the Managing Board and Senior Executive Officer Managing Director
    Junzo Yamamoto	Senior Executive Officer Managing Director	Senior Executive Officer
    Iwane Matsui	Senior Executive Officer	Executive Officer
    Hiroshi Kanda	Senior Executive Officer	Executive Officer

14. Appointments of Executive Officers (Newly Appointed)

    Name	New Position	Current Position
    Peng Zuo Hui	Executive Officer	President and CEO, Sysmex Shanghai Ltd.
    Tomokazu Yoshida	Executive Officer	Executive Vice President of Central Research Laboratories
    Kensuke Iizuka	Executive Officer	Executive Vice President of Corporate Business Planning Office

15. Retirement of Executive Officers (Completion of Contract Term)

Name	New Position	Current Position
Masayoshi Hayashi	Member of the Managing Board	Member of the Managing Board and Senior Executive Officer Senior Managing Director
Koji Tamura	Member of the Managing Board	Member of the Managing Board and Senior Executive Officer Managing Director
Michiaki Ishida	1	Senior Executive Officer
Takashi Goda	2	Senior Executive Officer

1. After retirement of the current position, he will become Adviser of Sysmex Corporation.

2. After retirement of the current position, he will become President and CEO of Sysmex CNA Co., Ltd.